Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Interim Report First Quarter 2017

First quarter · Net sales increased by 7% to SEK 115.0 (107.4) million. Adjusted to fixed exchange rates, net sales also increased by 7%. · Adjusted operating profit increased by 31% to SEK 44.4 (34.0) million. · Adjusted profit before tax increased by 43% to SEK 35.3 (24.6) million. · In February 2017, Diamorph AB (publ) acquired the final 10% of Diamorph Bearings AB and so today controls 100% of each of its subsidiaries. · In March 2017, Diamorph AB (publ) used part of the group’s surplus cash resources to make a voluntary partial repayment of SEK 50 million of its

Eltel’s Nomination Committee proposes Markku Moilanen as a new board member and revises its proposals for the AGM 2017 concerning the Board

Press release: 23.5.2017 at 8.00 CET The Nomination Committee of Eltel AB has unanimously resolved to propose Markku Moilanen as new member of Eltel’s Board of Directors. On 2 May 2017, the Nomination Committee announced its proposals for Eltel AB’s Annual General Meeting (AGM) to be held on 1 June 2017. The Nomination Committee hereby announces its revised proposal concerning the members of the Board of Directors to be presented at the AGM.Number of members of the Board of Directors Seven ordinary members of the Board of Directors with no deputy members. The remuneration for the

Ovako launches M-Steel Calculator – a digital service tool

Ovako has launched the M-Steel Calculator, a digital tool based on the company’s Steel Navigator platform, which guides customers in identifying the right machine settings based on steel properties and cutting tools. The M-Steel Calculator also allows customers to compare tool life and cutting speeds between M-Steel® from Ovako and conventional steel.“We are pleased to be able to offer our customers the M-Steel Calculator for comparison and verification of the correct machine settings. Similar digital tools on the market have until now been based only on the equipment and not the type of

Read original

Magnolia Bostad signs agreement to acquire two properties in Huddinge

Magnolia Bostad signs agreement to acquire Spendrup's old brewery, the properties Gambrinus 2 and Gambrinus 4, in Vårby. Magnolia Bostad will initiate work for a local plan for primarily residential purposes, comprising the development of approximately 1,500 residential unitsThe acquisition is covered by the framework agreement signed by Magnolia Bostad in November 2016 with Slättö. With the acquisition, Magnolia Bostad has signed agreements for all projects covered by the framework agreement. In total, the framework agreement comprises 13 residential projects, to be developed and sold to

Multiconsult ASA - Notice of extraordinary general meeting

An extraordinary general meeting of Multiconsult ASA will be held on 23 June 2017 at 12:00 CET at Felix Konferansesenter, Bryggetorget 3, Aker Brygge, Oslo.Notice of the extraordinary general meeting is attached hereto. All the documents to be processed at the extraordinary general meeting are available on the company's website www.multiconsult-ir.com. For more information, please contact:    Investor relations:           Mirza Koristovic, Head of Investor Relations           Phone: +47 93 87 05 25          E-mail: ir@multiconsult.no    Media:          Gaute Christensen,

Published preclinical results confirm IdeS potential in cancer immunotherapy

Hansa Medical AB (publ), a biopharmaceutical company developing novel immunomodulatory enzymes, announced today that preclinical data have been published in the peer-reviewed journal, Molecular Cancer Therapeutics (Järnum et al., Mol Cancer Ther May 22 2017 DOI: 10.1158/1535-7163.MCT-17-0108), confirming the potential of the company’s lead candidate IdeS in cancer immunotherapy.The published findings demonstrate how pre-treatment with IdeS in tumour animal models can increase the efficacy of currently available antibody based cancer therapies. Christian Kjellman, Senior Vice President R&

Multiconsult ASA - Proposal for new legal structure

The Board of Multiconsult ASA proposes to establish a new legal structure for the Multiconsult group. The company’s Norwegian operational activities will be demerged and then merged into a wholly-owned subsidiary. The purpose of the new legal structure is to establish a more efficient legal structure for the Multiconsult group.The Board of Multiconsult ASA has therefore decided to propose to its shareholders that the company’s business, as defined in a demerger plan dated 15 May 2017, is demerged to the newly established company MC Newco AS, followed by a merger of the business into

Appointment of new CEO of Hunter Group ASA, new chairman of Dwellop AS and a related party transaction

The board of directors of Hunter Group ASA ("Hunter Group" or the "Company") has appointed Mr. Vegard Urnes as new interim Chief Executive Officer ("CEO") of Hunter Group. To this effect, the Company has entered into a consultancy agreement with Middelborg AS, where Mr. Urnes is employed as Investment Manager. His employment as CEO in Hunter Group takes effect immediately. Mr. Urnes has over 15 years of experience from corporate finance, with main focus on the oil service sector. Mr. Urnes has previously worked with corporate finance at Goldman Sachs, ProCorp and NRP Securities, before

Director and Management share purchases and Orderly Market Agreements

The Marketing Group plc (“TMG” or the “Company” or the “Group”) is pleased to announce that it has been notified of the director and management share purchases detailed below.  Additionally, TMG is pleased to provide an update on the number of shareholders who have entered into the Orderly Market Agreement with the Company.Share Purchases Adam Graham, the Group’s CEO, has acquired 300,000 ordinary shares in the Company (“Shares”) at €0.75 per Share for a total value of €225,000 in an off market transaction with another shareholder.  Following this acquisition Adam Graham’s total

Kieku – the new personalised audio listening stream

Kieku  Labs, a Finnish independent media startup, today launched a new kind of audio listening service. Kieku’s key content aims to feed your mind with topics revolving around entrepreneurship and society, wellbeing and real-life stories. Based on machine learning, an algorithm generates a custom-made feed just for you, taking into account the types of content you listen to and the ones you skip. The beta service is available on kieku.com and initially as an iOS app in the Nordics and Estonia. “Imagine being stuck in traffic - radio plays content that is not

BrightCharger - charge in safety and protect your device battery life with a single touch

BrightCharger  aims to change the way people charge their devices. The innovative quality charger automatically stops devices from charging when their batteries are full, which protects battery lifespans, decreases hazards and eliminates energy wastage. The device also functions as a low energy consumption nightlight. With latest estimates currently placing the number of mobile devices at 12 billion, BrightCharger wants to help users make an impact on global consumption by giving them a simple way to responsibly charge various devices. “By using

Herantis Pharma granted a U.S. patent on therapeutic use of MANF

Herantis Pharma granted a U.S. patent on therapeutic use of MANF Herantis Pharma PlcCompany release 23 May 2017 at 9:00 am The United States Patent and Trademark Office ("USPTO") has issued to Herantis Pharma Plc ("Herantis") a patent titled "Neurotrophic factor MANF and uses thereof".  The patent number 9,592,270 is for the use of MANF, or mesencephalic astrocyte-derived neurotrophic factor, for the treatment of neurological diseases including Parkinson's disease, epilepsy, and ischemic brain injury. "MANF is the only known neurotrophic and neuroprotective factor similar to our

BerGenBio ASA: Results for the First Quarter 2017

Bergen, Norway, 23 May 2017 – BerGenBio ASA, a clinical-stage biopharmaceutical company developing novel, selective Axl kinase inhibitors for multiple cancer indications, announces its results for the first quarter 2017. A presentation of the results by the company’s senior management team will take place today at 10:00a.m. CET in Oslo - details below.Richard Godfrey, Chief Executive Officer of BerGenBio, commented: “During Q1 2017, BerGenBio has established a strong foundation from which to advance our development strategy for BGB324, a first-in-class, selective, oral Axl inhibitor,

EVRY intends to apply for a listing on Oslo Børs

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY JURISDICTION WHERE TO DO SO MIGHT CONSTITUTE A VIOLATION OF THE LOCAL SECURITIES LAWS OR REGULATIONS OF SUCH JURISDICTION. EVRY AS (“EVRY” or the “Company”) today announces its intention to launch an initial public offering (the "IPO") of its ordinary shares and to apply for a listing on Oslo Børs.The IPO will support EVRY’s strategy and growth plans, through contributing to further enhancement of EVRY’s public profile, and

BAKKAFROST: Operational EBIT of DKK 335 million for the first quarter of 2017

The Bakkafrost Group delivered a total operating EBIT of DKK 335.5 mil­lion in Q1 2017. Harvested volumes were 13.2 thousand tonnes gutted weight. The combined farming and VAP segments made an operational EBIT of DKK 320.2 million. The farming segment made an operational EBIT of DKK 373.2 million. The salmon spot prices continued in Q1 2017 on a high level from 2016, which was positive for the farming segment. The VAP segment realized higher prices, but is not matched by the high spot prices, and therefore the VAP segment had negative margins in Q1 2017. The VAP segment made an operational

Storebrand Livsforsikring AS: Report on Solvency and financial condition 2016

Storebrand ASA makes public the electronic version of the Solvency and financial condition report 2016 at https://www.storebrand.no/en/investor-relations. Lysaker, 22 May 2017 Contact: Head of IR Kjetil Ramberg Krøkje: kjetil.r.krokje@storebrand.no or (+47) 934 12 155 Storebrand's ambition is to deliver better pensions. Storebrand will deliver sustainable solutions adapted to the customer's individual situation, so that each person receives a better pension in a more sustainable world. Storebrand has about 40.000 corporate customers and 1.9 million individual customers, and is

Storebrand ASA: Solvency and financial condition report 2016

Storebrand ASA makes public the electronic version of the Solvency and financial condition report 2016 at https://www.storebrand.no/en/investor-relations. Lysaker, 22 May 2017 Contact: Head of IR Kjetil Ramberg Krøkje: kjetil.r.krokje@storebrand.no or (+47) 934 12 155 Storebrand's ambition is to deliver better pensions. Storebrand will deliver sustainable solutions adapted to the customer's individual situation, so that each person receives a better pension in a more sustainable world. Storebrand has about 40.000 corporate customers and 1.9 million individual customers, and is

UTA’s AbeXXa Biologics named one of 40 "Best University Startups 2017" by National Council of Entrepreneurial Tech Transfer

AbeXXa is identifying a new series of biomarkers or targets for cancer from the many thousands of proteins found within a tumor cell, a new field of research that could potentially result in immunotherapies that prove effective for a broad range of patientsAbeXXa Biologics, a faculty startup at The University of Texas at Arlington, was named one of the 40 “Best University Startups 2017” by the National Council of Entrepreneurial Tech Transfer, a Washington-based association of startup officers from the top research universities in the United States. AbeXXa Biologics co-founder and chief

Preterm birth linked to higher risk of heart failure

[PRESS RELEASE 2017-05-22] Babies born preterm run a higher risk of heart failure during childhood and adolescence than those born at full term, researchers at Karolinska Institutet in Sweden report. The registry-based study is published in The Journal of the American College of Cardiology (JACC).More and more babies survive increasingly preterm births. Babies born prematurely are exposed to life outside the womb at a time when their organs are yet to fully mature and their bodies are not entirely prepared for the radical transition from fetus to neonate. In recent years, scientists have

SUMMARY FROM ANNUAL GENERAL MEETING OF EPISURF MEDICAL AB (PUBL)

The shareholders of Episurf Medical AB (publ) (“Episurf” or the “Company”) gathered in Stockholm, Sweden, on Monday 22 May 2017 for the Annual General Meeting.The income statements and the balance sheets for the Company and the group were approved and the Board of Directors and the Managing Director were discharged from liability for the financial year 2016. The Meeting resolved to allocate the result in accordance with the proposal of the Board of Directors in the Annual Report. In accordance with the proposal by the Nomination Committee (i) Dennis Stripe, Saeid Esmaeilzadeh, Wilder

Ossur Hf : Transactions in relation to share buyback program

Announcement from Össur hf. No. 40/2017Reykjavík, 22 May 2017   On 1 December 2016, Össur hf. initiated a new share buy-back program, see Company announcement no. 96/2016. The purpose of the share buyback program is to reduce the Company's share capital and adjust the capital structure by distributing capital to shareholders in line with the Company's Capital Structure and Dividend Policy. The program will end no later than 30 November 2017. The Company may purchase up to 5,000,000 shares under the program, corresponding to 1.2% of the current share capital. The total

Sedana Medical AB (publ) publish 2016 annual report

An eventful year and a historic profitThe annual report is only available in Swedish; the information below is a summary with comments on the key figures. The interim report for the period 1 January – 31 March 2017 will although be available in English and will also include a consolidated income statement, balance sheet and cash flow analysis for the full financial year 2016. 1 January – 31 December 2016 in summary, consolidated figures · Net sales 32,155 TSEK (28,113 TSEK) · EBITDA 994 TSEK (-1,174 TSEK), corresponding to a EBITDA margin of 3.1% (-4.2%) · EBIT 618 TSEK (-1,

New findings on formation and malformation of blood vessels

[PRESS RELEASE 2017-05-22] In diseases like cancer, diabetes, rheumatism and stroke, a disorder develops in the blood vessels that exacerbates the condition and obstructs treatment. Researchers at Karolinska Institutet now show how blood vessels can normally change their size to create a functional circulatory system and how vascular malformation during disease can occur. In the study, published in Nature Cell Biology, the researchers managed to treat vascular malformation in mice, a discovery of potential significance to numerous vascular diseases.A healthy body has a perfect balance of

There are no items matching the current filter
There are no more items matching the current filter
Back to top